title: Editorial Comment from Dr Wu to Sulfoquinovosylacylpropanediol is a novel potent radiosensitizer in prostate cancer.
authors: Uro-Oncology Research Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA. BoyangJason.Wu@cshs.org.
authors: Boyang Jason
authors: BJ
authors: Wu
mesh_terms: D000818:Animals; D001808:Blood Vessels / Q000528:radiation effects*; D006017:Glycolipids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009389:Neovascularization, Pathologic / Q000532:radiotherapy*; D011471:Prostatic Neoplasms / Q000098:blood supply* / Q000532:radiotherapy*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*
chemical_list: D006017:Glycolipids; D011838:Radiation-Sensitizing Agents; C000605760:sulfoquinovosylacylpropanediol